Across
- 4. What is an individual or pharmaceutical company, governmental agency, academic institution, private organization, or other organisation called who takes responsibility for and initiates a BA or BE (in vivo or in vitro) study
- 10. The ____ diameter of an aerosol particle is equal to the diameter of a sphere of unit density whose gravimetric settling velocity is the same.
- 14. What is the term used for the remainder of the discharge from the inhaler that is inhaled into the remainder of the respiratory tract?
- 15. ____ is performed to confirm that the amount of drug discharged from the product and recovered from the mouthpiece/nosepiece adapter, induction port, and after-filter of the cascade impacted is within an acceptable range of the target-delivered label claim?
- 16. Which is the medium that is primarily intended for the culture of anaerobic bacteria?
- 18. A component or entity that may come into contact with a tertiary packaging component during the distribution, storage, transportation of the packaged article is known ____ component.
Down
- 1. What is the name of Cipla’s flagship respiratory initiative that has broadened its footprint in the UAE?
- 2. What is the API in Cipla’s advanced IV antibiotic drug ZEMDRI?
- 3. A column that has no packed solid support and in which the liquid stationary phase is deposited or chemically bonded to the inner surface of the column, is known as a ___ column.
- 5. _____ is the process of acquiring and evaluating data that establishes the biological safety of an individual degradation product or a given degradation profile at the level(s) specified.
- 6. The applicant’s QMS (quality management system) should include the design and implementation of efficient protocols including tools and procedures for study conduct to support participant’s rights, _____ and well-being and the reliability of study results.
- 7. Which glucagon-like peptide-1 (GLP-1) has been announced by Eli Lily and Cipla in an agreement to distribute in India under the Yurpeak brand?
- 8. In particular, analytical procedures should be validated to demonstrate ___ for the specified and unspecified degradation products.
- 9. Which manufacturing process step poses risk when nitrous acid is used for azide decomposition?
- 11. Under the agreement with Pfizer, which non-steroidal anti-inflammatory drug (NSAId) does Cipla have the sole right to distribute and sell in India?
- 12. For a ____, the core formulation(s) of the additional strength(s) should be qualitatively the same as that of the biobatch strength(s).
- 13. Cipla has exclusive rights in India for ____ inhalation powder, a non-injectable, rapid-acting inhaled insulin developed by the American company Mankind.
- 16. _____ assays serve multiple purposes in the characterization of protein products. These tests complement physiochemical analyses and are a quantifiable measure of the function of the protein product.
- 17. A packaging component that is in direct contact with, or may come into direct contact with the article, is known as ______ packaging component.